← back to search

Paul G. Schlegel

Universität Hamburg · DE
Area of research
Hematology · Immunology
Research interest
Research interests include Hematopoietic Stem Cell Transplantation, Immunotherapy and Immune Responses, CAR-T cell therapy research, and Glioma Diagnosis and Treatment.
h-index
24
citations
2,481
works
68
NIH funding
primary concept
email

Recent publications

Results of a multicenter phase I/II trial of TCRαβ and CD19-depleted haploidentical hematopoietic stem cell transplantation for adult and pediatric patients
Bone Marrow Transplantation 2021cited by 53position: middledoi
Spontaneous regression of a congenital high-grade glioma—a case report
Neuro-Oncology Advances 2021cited by 4position: middledoi
Nonmetastatic Medulloblastoma of Early Childhood: Results From the Prospective Clinical Trial HIT-2000 and An Extended Validation Cohort
Journal of Clinical Oncology 2020cited by 102position: middledoi
Treosulfan–fludarabine–thiotepa-based conditioning treatment before allogeneic hematopoietic stem cell transplantation for pediatric patients with hematological malignancies
Bone Marrow Transplantation 2020cited by 34position: middledoi
Gonadal Function after Busulfan Compared with Treosulfan in Children and Adolescents Undergoing Allogeneic Hematopoietic Stem Cell Transplant
Biology of Blood and Marrow Transplantation 2019cited by 64position: middledoi
Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia
Journal of Clinical Oncology 2016cited by 601position: middledoi
Haematopoietic stem cell transplantation for refractory Langerhans cell histiocytosis: outcome by intensity of conditioning
British Journal of Haematology 2015cited by 77position: middledoi
Initial Results from a Phase 2 Study of Blinatumomab in Pediatric Patients with Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
Blood 2014cited by 24position: middledoi
Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial
The Lancet 2012cited by 375position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Franco Locatelli · Assistance Publique – Hôpitaux de Paris3 papers (2014–2020)Peter Bader · Children's Clinical University Hospital3 papers (2014–2020)Rupert Handgretinger · University College London3 papers (2014–2021)Kuolung Hu · Ionis Pharmaceuticals (United States)2 papers (2014–2016)Steven G. DuBois · Harvard University2 papers (2014–2016)Benoît Brethon · Sorbonne Paris Cité2 papers (2014–2016)C. Michel Zwaan · Erasmus MC2 papers (2014–2016)Phillip Barnette · Oregon National Primate Research Center2 papers (2014–2016)Gerhard Zugmaier · Amgen (Germany)2 papers (2014–2016)Matthias Eyrich · Max Delbrück Center2 papers (2021–2021)Chiara Messina · University of Insubria2 papers (2014–2016)Deepa Bhojwani · Glenmark Pharmaceuticals (India)2 papers (2014–2016)Lia Gore · The University of Texas Health Science Center at Houston2 papers (2014–2016)Tanya Trippett · Memorial Sloan Kettering Cancer Center2 papers (2014–2016)Carmelo Rizzari · Fondazione Lanza2 papers (2014–2016)Maureen M. O’Brien · University of Colorado Anschutz Medical Campus2 papers (2014–2016)Johann Greil · Heidelberg University2 papers (2020–2021)James A. Whitlock · University of Toronto2 papers (2014–2016)Arend von Stackelberg · Charité - Universitätsmedizin Berlin2 papers (2014–2016)Alexandra H. Filipovich · NewYork–Presbyterian Hospital1 papers (2015–2015)